Analysis of Long Noncoding RNAs in Aila-Induced Non-Small Cell Lung Cancer Inhibition

Chen, Lin; Wu, Chen; Wang, Heming; Chen, Sinuo; Ma, Danhui; Tao, Ye; Wang, Xingye; Luan, Yanhe; Wang, Tiedong; Shi, Yan; Song, Guangqi; Zhao, Yicheng; Dong, Xijun; Wang, Bingmei

doi:10.3389/fonc.2021.652567

Cited by 4 publications

(9 citation statements)

References 56 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some lncRNAs have the potential to serve as biomarkers for diagnosing and monitoring tumors due to their specific expression during tumor occurrence and development ( Qi and Du, 2013 ). DUXAP8 is significantly overexpressed in cancer tissues compared to nearby non-tumor tissues, according to observations ( Ma et al, 2017b ; Du et al, 2019 ; Chen et al, 2020a ; Chen et al, 2020b ; He et al, 2020 ; Yin et al, 2020 ; Chen et al, 2021a ). Thus, we first conducted this meta-analysis to examine if there was a correlation between lncRNA DUXAP8 expression and overall survival in order to better evaluate its predictive potential.…”

Section: Discussionmentioning

confidence: 93%

“…We excluded duplicate studies, studies irrelevant to the research subject, and studies that did not provide sufficient data. Therefore, there are a total of 25 studies that meet the final analysis conditions ( Ma et al, 2017b ; Xu et al, 2017 ; Lian et al, 2018 ; Lin et al, 2018 ; Du et al, 2019 ; Jiang et al, 2019 ; Chen et al, 2020a ; Chen et al, 2020b ; He et al, 2020 ; Hu et al, 2020 ; Nie et al, 2020 ; Wang et al, 2020 ; Wei et al, 2020 ; Yin et al, 2020 ; Zhang et al, 2020 ; Zhao et al, 2020 ; Chen et al, 2021a ; Li et al, 2021a ; Arabpour et al, 2021 ; Yang et al, 2021a ; Chen et al, 2021b ; Guan et al, 2021 ; Pang and Yang, 2021 ; Xing et al, 2021 ; Zhai et al, 2021 ). Moreover, the main features of the included studies have been summarized in Supplementary Table S1 .…”

Section: Resultsmentioning

confidence: 99%

“…All the included studies from 2016 to 2021 have been implemented and published in China except one study carried out in America. In total, 17 cancer types were included in our study: gastric cancer (GC) ( Ma et al, 2017b ), non-small cell lung cancer (NSCLC) ( Yin et al, 2020 ; Chen et al, 2021a ), cervical cancer (CC) ( Chen et al, 2020b ), oral cancer (OC) ( Chen et al, 2020a ), colorectal cancer (CRC) ( Du et al, 2019 ; He et al, 2020 ), papillary thyroid carcinoma (PTC) ( Pang and Yang, 2021 ), LGG ( Zhao et al, 2020 ), PAAD ( Lian et al, 2018 ), hepatocellular carcinoma (HCC) ( Jiang et al, 2019 ; Hu et al, 2020 ; Wang et al, 2020 ; Wei et al, 2020 ; Zhang et al, 2020 ; Guan et al, 2021 ), acute myeloid Leukemia (AML) ( Zhai et al, 2021 ), BLCA ( Lin et al, 2018 ), KIRC ( Xing et al, 2021 ), neuroblastoma ( Nie et al, 2020 ), ovarian cancer ( Li et al, 2021a ), osteosarcoma ( Yang et al, 2021a ), renal cell carcinoma (RCC) ( Xu et al, 2017 ), melanoma ( Chen et al, 2021b ), breast cancer (BC) ( Arabpour et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

“…There were 25 studies ( Ma et al, 2017b ; Xu et al, 2017 ; Lian et al, 2018 ; Lin et al, 2018 ; Du et al, 2019 ; Jiang et al, 2019 ; Chen et al, 2020a ; Chen et al, 2020b ; He et al, 2020 ; Hu et al, 2020 ; Nie et al, 2020 ; Wang et al, 2020 ; Wei et al, 2020 ; Yin et al, 2020 ; Zhang et al, 2020 ; Zhao et al, 2020 ; Chen et al, 2021a ; Li et al, 2021a ; Arabpour et al, 2021 ; Yang et al, 2021a ; Chen et al, 2021b ; Guan et al, 2021 ; Pang and Yang, 2021 ; Xing et al, 2021 ; Zhai et al, 2021 ), consisting of 4,757 patients, included for OS analysis. A correlation analysis has been performed to explore between DUXAP8 and the poor OS in patients diagnosed with cancer.…”

Section: Resultsmentioning

confidence: 99%

“…DUXAP8 has a length of around 2,307 bp. DUXAP8 is significantly overexpressed in cancer tissues compared to nearby non-tumor tissues, according to observations ( Ma et al, 2017b ; Du et al, 2019 ; Chen et al, 2020a ; Chen et al, 2020b ; He et al, 2020 ; Yin et al, 2020 ; Chen et al, 2021a ). DUXAP8 exerts an essential role in tumorigenesis, proliferation, migration, invasion, and inhibition of apoptosis, which means that DUXAP8 acts as an oncogene in the occurrence and development of various malignant tumors ( Jiang et al, 2019 ; Hu et al, 2020 ; Wang et al, 2020 ; Wei et al, 2020 ; Zhang et al, 2020 ; Guan et al, 2021 ).…”

Section: Introductionmentioning

confidence: 93%

See 4 more Smart Citations

LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis

Wang

Jiang²,

Zhang³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Dual homeoboxes A pseudogene 8 (DUXAP8) is a newly discovered long noncoding RNA that has been shown to function as an oncogene in a variety of human malignant cancers. By integrating available data, this meta-analysis sought to determine the relationship between clinical prognosis and DUXAP8 expression levels in diverse malignancies.Materials and methods: A systematic search was performed to identify eligible studies from several electronic databases from their inception to 25 October 2021. Pooled odds ratios and hazard ratios with 95% CI were used to estimate the association between DUXAP8 expression and survival. For survival analysis, the Kaplan-Meier method and COX analysis were used. Furthermore, we utilized Spearman’s correlation analysis to explore the correlation between DUXAP8 and tumor mutational burden (TMB), microsatellite instability (MSI), the related genes of mismatch repair (MMR), DNA methyltransferases (DNMTs), and immune checkpoint biomarkers.Results: Our findings indicated that overexpression of DUXAP8 was related to poor overall survival (OS) (HR = 1.63, 95% CI, 1.49–1.77, p < 0.001). In addition, elevated DUXAP8 expression was closely related to poor OS in several cancers in the TCGA database. Moreover, DUXAP8 expression has been associated with TMB, MSI, and MMR in a variety of malignancies.Conclusion: This study revealed that DUXAP8 might serve as a prognostic biomarker and potential therapeutic target for cancer. It can be used to improve cancer diagnosis, discover potential treatment targets, and improve prognosis.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 93%

See 3 more Smart Citations

LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis

Wang

Jiang²,

Zhang³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

Creation of Value Chains for the Sustainability of Control and Eradication Actions on Ailanthus altissima (Mill.) Swingle

Nunes

2022

Environments

View full text Add to dashboard Cite

Actions to control and eradicate Ailanthus altissima (Mill.) Swingle are essential to the prevention of uncontrolled growth and expansion of this species and its competition with native species. This competition leads to biodiversity and productivity losses in forests. The present study evaluated the potential to create value chains to maintain the sustainability of control actions through the energy recovery of collected A. altissima biomass. Other possibilities were also discussed, such as the extraction of allelopathic compounds. For this purpose, and to assess the potential for energy recovery, samples of A. altissima were collected and analyzed in the laboratory to discuss the potential of using extracted compounds in nature-based applications, and a literature review was carried out. It was found that, although there is potential for the use of these biomasses for energy production, the high levels of chlorine and heavy metals pose some obstacles to their large-scale use, mainly due to their corrosive potential. On the other hand, the extraction of allelopathic compounds was shown to be potentially interesting for use in the control of other invasive species. Used in this application, it may be possible to create value chains to sustain, control, and eradicate the actions of this invasive species.

show abstract

Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer

Geng,

Zhao,

et al. 2023

IJMS

View full text Add to dashboard Cite

Lung cancer is a malignant tumor with one of the highest morbidity and mortality rates in the world. Approximately 80–85% of lung cancer is diagnosed as non-small lung cancer (NSCLC), and its 5-year survival rate is only 21%. Cisplatin is a commonly used chemotherapy drug for the treatment of NSCLC. Its efficacy is often limited by the development of drug resistance after long-term treatment. Therefore, determining how to overcome cisplatin resistance, enhancing the sensitivity of cancer cells to cisplatin, and developing new therapeutic strategies are urgent clinical problems. Z-ligustilide is the main active ingredient of the Chinese medicine Angelica sinensis, and has anti-tumor activity. In the present study, we investigated the effect of the combination of Z-ligustilide and cisplatin (Z-ligustilide+cisplatin) on the resistance of cisplatin-resistant lung cancer cells and its mechanism of action. We found that Z-ligustilide+cisplatin decreased the cell viability, induced cell cycle arrest, and promoted the cell apoptosis of cisplatin-resistant lung cancer cells. Metabolomics combined with transcriptomics revealed that Z-ligustilide+cisplatin inhibited phospholipid synthesis by upregulating the expression of phospholipid phosphatase 1 (PLPP1). A further study showed that PLPP1 expression was positively correlated with good prognosis, whereas the knockdown of PLPP1 abolished the effects of Z-ligustilide+cisplatin on cell cycle and apoptosis. Specifically, Z-ligustilide+cisplatin inhibited the activation of protein kinase B (AKT) by reducing the levels of phosphatidylinositol 3,4,5-trisphosphate (PIP3). Z-ligustilide+cisplatin induced cell cycle arrest and promoted the cell apoptosis of cisplatin-resistant lung cancer cells by inhibiting PLPP1-mediated phospholipid synthesis. Our findings demonstrate that the combination of Z-Ligustilide and cisplatin is a promising approach to the chemotherapy of malignant tumors that are resistant to cisplatin.

show abstract

Analysis of Long Noncoding RNAs in Aila-Induced Non-Small Cell Lung Cancer Inhibition

Cited by 4 publications

References 56 publications

LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis

LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis

Creation of Value Chains for the Sustainability of Control and Eradication Actions on Ailanthus altissima (Mill.) Swingle

Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer

Contact Info

Product

Resources

About